A Study of BNT162b2 COVID-19 Vaccine Given as a Booster Dose in Healthy Adults Aged 60 Years and Older in Israel who had Already Received BNT162b2 COVID-19 Vaccine Before
Substudy F Final Report: A Phase 3 Master Protocol to Evaluate Additional Dose(s) of BNT162b2 in Healthy Individuals Previously Vaccinated With BNT162b2
Category & Conditions: Vaccine-related Conditions
Medicine: PF-07302048 (BNT162)
ClinicalTrials.gov Identifier (NCT): NCT04955626
Protocol ID: C4591031 SSF
PrintDownloadOpen Plain Language Summary Result: Click here